ApoE Promotes the Proteolytic Degradation of Aβ

Bales, 1997, Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition, Nat. Genet., 17, 263, 10.1038/ng1197-263 Bateman, 2006, Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo, Nat. Med., 12, 856, 10.1038/nm1438 Beaven, 2006, Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia, Annu. Rev. Med., 57, 313, 10.1146/annurev.med.57.121304.131428 Bell, 2007, Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system, J. Cereb. Blood Flow Metab., 27, 909, 10.1038/sj.jcbfm.9600419 Burns, 2006, The effects of ABCA1 on cholesterol efflux and Abeta levels in vitro and in vivo, J. Neurochem., 98, 792, 10.1111/j.1471-4159.2006.03925.x Cao, 2007, Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics, Curr. Alzheimer Res., 4, 179, 10.2174/156720507780362173 Comery, 2005, Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease, J. Neurosci., 25, 8898, 10.1523/JNEUROSCI.2693-05.2005 Deane, 2004, LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms, Neuron, 43, 333, 10.1016/j.neuron.2004.07.017 DeMattos, 2004, ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo, Neuron, 41, 193, 10.1016/S0896-6273(03)00850-X Denis, 2004, Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1), J. Biol. Chem., 279, 7384, 10.1074/jbc.M306963200 Dergunov, 2000, Conformation of apolipoprotein E both in free and in lipid-bound form may determine the avidity of triglyceride-rich lipoproteins to the LDL receptor: structural and kinetic study, Biochim. Biophys. Acta, 1484, 14, 10.1016/S1388-1981(99)00196-1 Dolev, 2004, A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade, Proc. Natl. Acad. Sci. USA, 101, 13909, 10.1073/pnas.0404458101 Fagan, 1999, Unique lipoproteins secreted by primary astrocytes from wild type, apoE (−/−), and human apoE transgenic mice, J. Biol. Chem., 274, 30001, 10.1074/jbc.274.42.30001 Farris, 2003, Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo, Proc. Natl. Acad. Sci. USA, 100, 4162, 10.1073/pnas.0230450100 Farris, 2007, Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy, Am. J. Pathol., 171, 241, 10.2353/ajpath.2007.070105 Fisher, 1999, Lipid binding-induced conformational changes in the N-terminal domain of human apolipoprotein E, J. Lipid Res., 40, 93, 10.1016/S0022-2275(20)33343-5 Fukumoto, 2002, Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists increases secreted Abeta levels, J. Biol. Chem., 277, 48508, 10.1074/jbc.M209085200 Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 Harr, 1996, Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease, J. Neurochem., 66, 2429, 10.1046/j.1471-4159.1996.66062429.x Hemming, 2007, Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease, PLoS Med., 4, e262, 10.1371/journal.pmed.0040262 Hirsch-Reinshagen, 2004, Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain, J. Biol. Chem., 279, 41197, 10.1074/jbc.M407962200 Hirsch-Reinshagen, 2005, The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease, J. Biol. Chem., 280, 43243, 10.1074/jbc.M508781200 Holtzman, 2001, Role of apoe/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy, J. Mol. Neurosci., 17, 147, 10.1385/JMN:17:2:147 Holtzman, 2004, In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathology, J. Mol. Neurosci., 23, 247, 10.1385/JMN:23:3:247 Hsiao, 1995, Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins, Neuron, 15, 1203, 10.1016/0896-6273(95)90107-8 Iwata, 2000, Identification of the major Abeta1–42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition, Nat. Med., 6, 143, 10.1038/77399 Iwata, 2001, Metabolic regulation of brain Abeta by neprilysin, Science, 292, 1550, 10.1126/science.1059946 Jacobsen, 2006, Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease, Proc. Natl. Acad. Sci. USA, 103, 5161, 10.1073/pnas.0600948103 Jiang, 2003, Enlargement of high density lipoprotein in mice via liver X receptor activation requires apolipoprotein E and is abolished by cholesteryl ester transfer protein expression, J. Biol. Chem., 278, 49072, 10.1074/jbc.M304274200 Kawarabayashi, 2001, Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease, J. Neurosci., 21, 372, 10.1523/JNEUROSCI.21-02-00372.2001 Koch, 2001, Characterization of four lipoprotein classes in human cerebrospinal fluid, J. Lipid Res., 42, 1143, 10.1016/S0022-2275(20)31605-9 Koenigsknecht, 2004, Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism, J. Neurosci., 24, 9838, 10.1523/JNEUROSCI.2557-04.2004 Koistinaho, 2004, Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides, Nat. Med., 10, 719, 10.1038/nm1058 Koldamova, 2001, Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity, Biochemistry, 40, 3553, 10.1021/bi002186k Koldamova, 2003, 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion, J. Biol. Chem., 278, 13244, 10.1074/jbc.M300044200 Koldamova, 2005, Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice, J. Biol. Chem., 280, 43224, 10.1074/jbc.M504513200 Koldamova, 2005, The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease, J. Biol. Chem., 280, 4079, 10.1074/jbc.M411420200 Kurochkin, 1994, Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme, FEBS Lett., 345, 33, 10.1016/0014-5793(94)00387-4 LaDu, 1995, Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid, J. Biol. Chem., 270, 9039, 10.1074/jbc.270.16.9039 Ladu, 2006, Self-Assembly of HEK Cell-Secreted ApoE Particles Resembles ApoE Enrichment of Lipoproteins as a Ligand for the LDL Receptor-Related Protein, Biochemistry, 45, 381, 10.1021/bi051765s Lee, 2005, ATP-binding cassette transporter AI and its role in HDL formation, Curr. Opin. Lipidol., 16, 19, 10.1097/00041433-200502000-00005 Lefterov, 2007, Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment, Mol. Neurodegener., 2, 20, 10.1186/1750-1326-2-20 Leissring, 2003, Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death, Neuron, 40, 1087, 10.1016/S0896-6273(03)00787-6 Liang, 2004, A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes, J. Neurochem., 88, 623, 10.1111/j.1471-4159.2004.02183.x Morikawa, 2005, Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-beta, Neurobiol. Dis., 19, 66, 10.1016/j.nbd.2004.11.005 Qiu, 2006, Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis, Neurobiol. Aging, 27, 190, 10.1016/j.neurobiolaging.2005.01.004 Qiu, 1998, Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation, J. Biol. Chem., 273, 32730, 10.1074/jbc.273.49.32730 Riddell, 2007, The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease, Mol. Cell. Neurosci., 34, 621, 10.1016/j.mcn.2007.01.011 Rogers, 2002, Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide, Glia, 40, 260, 10.1002/glia.10153 Roses, 1996, Apolipoprotein E alleles as risk factors in Alzheimer's disease, Annu. Rev. Med., 47, 387, 10.1146/annurev.med.47.1.387 Roses, 1995, Influence of the susceptibility genes apolipoprotein E-epsilon 4 and apolipoprotein E-epsilon 2 on the rate of disease expressivity of late-onset Alzheimer's disease, Arzneimittelforschung, 45, 413 Russo, 1998, Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease, Proc. Natl. Acad. Sci. USA, 95, 15598, 10.1073/pnas.95.26.15598 Shen, 1995, Solvent effects on self-assembly of beta-amyloid peptide, Biophys. J., 69, 640, 10.1016/S0006-3495(95)79940-4 Smith, 2004, ABCA1 mediates concurrent cholesterol and phospholipid efflux to apolipoprotein A-I, J. Lipid Res., 45, 635, 10.1194/jlr.M300336-JLR200 Sun, 2003, Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion, J. Biol. Chem., 278, 27688, 10.1074/jbc.M300760200 Tanzi, 2005, Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective, Cell, 120, 545, 10.1016/j.cell.2005.02.008 Tanzi, 2004, Clearance of Alzheimer's Abeta peptide: the many roads to perdition, Neuron, 43, 605 Tokuda, 2000, Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides, Biochem. J., 348, 359, 10.1042/0264-6021:3480359 Wahrle, 2004, ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE, J. Biol. Chem., 279, 40987, 10.1074/jbc.M407963200 Wahrle, 2005, Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease, J. Biol. Chem., 280, 43236, 10.1074/jbc.M508780200 Wahrle, 2008, Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease, J. Clin. Invest., 118, 671 Walsh, 2004, Deciphering the molecular basis of memory failure in Alzheimer's disease, Neuron, 44, 181, 10.1016/j.neuron.2004.09.010 Wang, 2001, ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein, J. Biol. Chem., 276, 23742, 10.1074/jbc.M102348200 Wang, 2002, Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration, Proc. Natl. Acad. Sci. USA, 99, 13878, 10.1073/pnas.172510899 Xu, 2000, Isolation and characterization of apolipoproteins from murine microglia. Identification of a low density lipoprotein-like apolipoprotein J-rich but E-poor spherical particle, J. Biol. Chem., 275, 31770, 10.1074/jbc.M002796200 Xu, 2006, Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus, J. Neurosci., 26, 4985, 10.1523/JNEUROSCI.5476-05.2006 Zander, 2002, Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma, J. Neurochem., 81, 1052, 10.1046/j.1471-4159.2002.00899.x Zelcer, 2006, Liver X receptors as integrators of metabolic and inflammatory signaling, J. Clin. Invest., 116, 607, 10.1172/JCI27883 Zelcer, 2007, Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors, Proc. Natl. Acad. Sci. USA, 104, 10601, 10.1073/pnas.0701096104 Zlokovic, 2005, Neurovascular pathways and Alzheimer amyloid beta-peptide, Brain Pathol., 15, 78, 10.1111/j.1750-3639.2005.tb00103.x